PLK1 and non-small cell lung carcinoma: PLK1, a critical oncogenic kinase overexpressed in various cancers, has emerged as a promising therapeutic target, with several inhibitors (e.g., BI-2536) that previously underwent clinical trials for solid tumors, including NSCLC [30, 31, 33, 35, 43].